Clinical Trial Update: An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS) [Phase 2, Phase 3]

View source ↗

Summary

An international, multicenter Phase 2/3 randomized, double-blind, parallel-group, vehicle-controlled study is evaluating the efficacy and safety of diacerein 1%…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epidermolysis Bullosa Simplex

Drugs mentioned

• Diacerein 1% ointment (diacerein)

Snippet

Sponsor: TWi Biotechnology, Inc. | Conditions: Generalized Epidermolysis Bullosa Simplex | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING